Aerosolized Chemotherapy
Frédéric Gagnadoux, J. Hureaux, Laurent Vecellio et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2008
Regional chemotherapy has been proposed as a treatment modality in a number of cancer settings. In primary or metastatic lung cancer, administration of chemotherapy via inhalation could increase exposure of lung tumor to the drug, while minimizing systemic side effects. Several proof of concept studies in animal models of metastatic or primary lung cancer have demonstrated the safety, pharmacokinetic advantage, and antitumor effect of aerosol administration of several chemotherapeutic agents including doxorubicin, gemcitabine and liposome-encapsulated formulations of paclitaxel and 9-nitrocamptothecin (9-NC). Recent phase I studies have demonstrated the feasibility of aerosol delivery of doxorubicin and liposomal formulations of 9-NC and cisplatin in patients with primary and metastatic lung cancer with a limited pharmacokinetic profile consistent with the observed low systemic toxicity. Further studies integrating safety, pharmacokinetic, and efficacy considerations are required to determine whether there is a place for local administration of chemotherapy via inhalation in lung cancer.
Cited by 132 works. doi:10.1089/jamp.2007.0656
Authors
- Frédéric Gagnadoux
- J. Hureaux
- Laurent Vecellio
- Thierry Urban
- Alain Le Pape
- Isabelle Valo
- J. Montharu
- Valérie Leblond
- Michèle Boisdron‐Celle
- Stéphanie Lerondel
- Caroline Majoral
- P. Diot
- Jean L. Racineux
- Étienne Lemarié
References
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Cancer Statistics, 2003
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
- Drug penetration in solid tumours
- Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications
- Interstitial Lung Disease Induced by Drugs and Radiation
- Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481)
- Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings.
- Quality of Life of Long-Term Survivors of Non–Small-Cell Lung Cancer
- Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.